Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

We have engineered recombinant (r) Modified Vaccinia Ankara (MVA) to express multiple antigens under the control of either of two related vaccinia synthetic promoters (pSyn) with early and late transcriptional activity or the modified H5 (mH5) promoter which has predominant early activity. We sequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhongde, Martinez, Joy, Zhou, Wendi, La Rosa, Corinna, Srivastava, Tumul, Dasgupta, Anindya, Rawal, Ravindra, Li, Zhongqui, Britt, William J., Diamond, Don
Formato: Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821965/
https://www.ncbi.nlm.nih.gov/pubmed/19969118
http://dx.doi.org/10.1016/j.vaccine.2009.11.056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821965/
https://www.ncbi.nlm.nih.gov/pubmed/19969118
http://dx.doi.org/10.1016/j.vaccine.2009.11.056

Ejemplares similares